Deregulation of lysine methylation signalling has emerged as a common aetiological factor in cancer pathogenesis, with inhibitors of several histone lysine methyltransferases (KMTs) being developed as chemotherapeutics 1 . The largely cytoplasmic KMT SMYD3 (SET and MYND domain containing protein 3) is overexpressed in numerous human tumours 2-4 . However, the molecular mechanism by which SMYD3 regulates cancer pathways and its relationship to tumorigenesis in vivo are largely unknown. Here we show that methylation of MAP3K2 by SMYD3 increases MAP kinase signalling and promotes the formation of Ras-driven carcinomas. Using mouse models for pancreatic ductal adenocarcinoma and lung adenocarcinoma, we found that abrogating SMYD3 catalytic activity inhibits tumour development in response to oncogenic Ras. We used protein array technology to identify the MAP3K2 kinase as a target of SMYD3. In cancer cell lines, SMYD3-mediated methylation of MAP3K2 at lysine 260 potentiates activation of the Ras/Raf/MEK/ERK signalling module and SMYD3 depletion synergizes with a MEK inhibitor to block Rasdriven tumorigenesis. Finally, the PP2A phosphatase complex, a key negative regulator of the MAP kinase pathway, binds to MAP3K2 and this interaction is blocked by methylation. Together, our results elucidate a new role for lysine methylation in integrating cytoplasmic kinase-signalling cascades and establish a pivotal role for SMYD3 in the regulation of oncogenic Ras signalling.
Deregulation of lysine methylation signalling has emerged as a common aetiological factor in cancer pathogenesis, with inhibitors of several histone lysine methyltransferases (KMTs) being developed as chemotherapeutics 1 . The largely cytoplasmic KMT SMYD3 (SET and MYND domain containing protein 3) is overexpressed in numerous human tumours [2] [3] [4] . However, the molecular mechanism by which SMYD3 regulates cancer pathways and its relationship to tumorigenesis in vivo are largely unknown. Here we show that methylation of MAP3K2 by SMYD3 increases MAP kinase signalling and promotes the formation of Ras-driven carcinomas. Using mouse models for pancreatic ductal adenocarcinoma and lung adenocarcinoma, we found that abrogating SMYD3 catalytic activity inhibits tumour development in response to oncogenic Ras. We used protein array technology to identify the MAP3K2 kinase as a target of SMYD3. In cancer cell lines, SMYD3-mediated methylation of MAP3K2 at lysine 260 potentiates activation of the Ras/Raf/MEK/ERK signalling module and SMYD3 depletion synergizes with a MEK inhibitor to block Rasdriven tumorigenesis. Finally, the PP2A phosphatase complex, a key negative regulator of the MAP kinase pathway, binds to MAP3K2 and this interaction is blocked by methylation. Together, our results elucidate a new role for lysine methylation in integrating cytoplasmic kinase-signalling cascades and establish a pivotal role for SMYD3 in the regulation of oncogenic Ras signalling.
The Ras family of oncogenes is activated in a large fraction of human cancers 5 . To explore possible connections between KMTs and human cancers driven by activation of Ras, we surveyed the level of expression for 54 known and candidate human KMT genes in pancreas ductal adenocarcinoma (PDAC), a cancer nearly universally initiated by oncogenic Ras mutations. We found that five KMT-encoding genes (SMYD3, MLL5 (also known as KMT2E), EZH2, SETD5 and WHSC1L1) were consistently upregulated in human data sets (Extended Data Fig. 1a-c) . SMYD3, which showed the most significant correlation with PDAC in our metaanalysis, is reported to be overexpressed in several cancers with elevated Ras activity 2,3 , and SMYD3 protein expression increases with PDAC development (Extended Data Fig. 2a, b ). On the basis of these results, we postulated that SMYD3 might have a role in Ras-driven tumorigenesis.
Little is known regarding SMYD3 cancer-related function in vivo. We previously generated Smyd3 mutant mice, which develop normally, and are viable and fertile (Extended Data Fig. 2d ; data not shown; ref. 6 ). To investigate the role of SMYD3 in Ras-driven cancers, Smyd3 mutant mice were crossed with mice harbouring a loxP-Stop-loxP KrasG12D knock-in allele (Kras 1/LSL-G12D ), which allows for the controlled induction of oncogenic K-Ras and the initiation of tumours in distinct organs, including the lung and the pancreas 7, 8 . PDAC is thought to arise from the transdifferentiation of acinar cells into duct-like cells upon activation of Ras signalling 9, 10 . We observed induction of SMYD3 expression during this process in mice with pancreas-specific activation of K-Ras ( Fig. 1a ) and in an ex vivo acinar-to-ductal metaplasia (ADM) assay 11 (Fig. 1b ). In this assay, SMYD3 was required for efficient duct formation from acinar cells ( Fig. 1c, d) . In vivo, ADM and PDAC initiation are triggered in young Kras mutant mice by inducing severe acute pancreatitis via repeated injections of caerulein 12 (Fig. 1e ). In this system, Smyd3 deletion reduced the appearance of pancreatic intra-epithelial neoplasia (PanIN) brought on by Kras activation, as determined by histopathological analysis and decreased signal for both phosphorylated ERK1/2 (pERK1/2, a downstream marker of Ras activity) and MUC5 (a marker of PanINs) ( Fig. 1f, g) . In the absence of a pancreatitis trigger, PanIN lesions develop by 6 months in p48 1/Cre ;Kras 1/LSL-G12D mice 8 , a process that was attenuated by Smyd3 loss (Fig. 1h ; Extended Data Fig. 3a ). Next, to study PDAC growth and to perform survival studies, we used the p48 1/Cre ;Kras 1/LSL-G12D ;p53 lox/lox (Kras;p53) mutant model (p48 and p53 are also known as Ptf1a and Trp53, respectively), which is characterized by rapid PanIN-to-PDAC progression and malignant transformation with 100% penetrance in a relatively short latency (,50-60 days) 13 . At autopsy, the pancreatic tissue from Kras;p53 mutant mice was entirely occupied by transformed cells, whereas areas of normal pancreatic tissue remained in Kras;p53;Smyd3 mutant mice (Extended Data Fig. 3b , c). Furthermore, loss of Smyd3 extended the lifespan of the animals ( Fig. 1i ) and resulted in reduced levels of the PDAC biomarker pERK1/2 in biopsy samples ( Fig. 1j ; Extended Data Fig. 3b ). Notably, K-Ras expression was not affected by SMYD3 deletion (Extended Data Fig. 3f ). Based on these data, we conclude that SMYD3 is required for efficient initiation of pancreatic cancer by oncogenic K-Ras.
Oncogenic activation of the Ras pathway is a frequent event in lung adenocarcinoma, a cancer that also shows high SMYD3 expression (Extended Data Figs 1d and 2c). Intratracheal injection of an adenovirus expressing the Cre recombinase (Ad-Cre) in adult Kras 1/LSL-G12D mice led to the development of atypical adenomatous hyperplasia (AAH) and adenomas in the lungs within 12 weeks 7 , irrespective of Smyd3 status ( Fig. 2a, b ; Extended Data Fig. 3d ). In contrast, at 16 and 20 weeks or more after Ad-Cre infection, mice lacking Smyd3 showed significantly smaller and less advanced tumours than control mice ( Fig. 2a , c, d; Extended Data Fig. 3d ; data not shown). Specifically, quantification of tumour grade indicated that Smyd3 loss impeded the critical transition from adenoma to adenocarcinoma ( Fig. 2c ), which was also observable in total levels of Ras ( Fig. 2f ; Extended Data Figs 2a and 3f). Together, these observations indicate that SMYD3 promotes Ras-driven cancer development and progression in vivo.
Depletion of SMYD3 by RNA-mediated interference (RNAi) using a short hairpin RNA (shRNA) strategy in LKR10 mouse cells (a LACderived cell line 16 ), A549 (a human LAC cell line) and CFPac1 (a human PDAC cell line) reduced the proliferation rates for all three cell types, and inhibited their ability to grow in anchorage-independent condition (Extended Data Fig. 4a-c ). Furthermore, knockdown of SMYD3 in CFPac1 cells inhibited tumour growth in mouse xenograft experiments (Extended Data Fig. 4d-f ). Thus, SMYD3 acts to maintain a number of tumorigenic characteristics in mouse and human cancer cell lines driven by oncogenic Ras.
Next, wild-type SMYD3, a catalytically inactive form (SMYD3(F183A)) 6 , or vector control were co-expressed with the Cre recombinase in the lungs of Kras;Smyd3 mutant mice by lentiviral transduction (Extended Data Fig. 5a ). Complementation of wild-type SMYD3 into the lungs of Kras;Smyd3 mutant mice resulted in a higher tumour burden and pERK1/2 signal relative to the control Cre-alone infection and expression of mutant SMYD3(F183A) ( Fig. 3a-c) . Reconstitution experiments also demonstrated that SMYD3 catalytic activity is required for pancreatic ADM (Extended Data Fig. 5b , c). We previously reported that SMYD3 methylates histone H4 at lysine 5 (H4K5) and not at other lysines on histones 6 . However, in LAC and PDAC cells and tumours, virtually all SMYD3 is present in the cytoplasm ( Fig. 1a and Extended Data Figs 2a, c, 3e and 6b), indicating that the cancer-relevant substrate in these cell types is unlikely to be nuclear H4K5 but rather a cytoplasmic protein.
In a biochemical screen for SMYD3 targets on a protein array platform containing more than 9,000 potential substrates 17 , the only candidate to be methylated by SMYD3 in three independent experiments was the MAP kinase pathway component MAP3K2 (Extended Data Fig. 6a ). As shown in Fig. 3d , recombinant wild-type SMYD3, but not the catalytically dead SMYD3(F183A) mutant, methylated recombinant MAP3K2 in vitro. Using a mutagenesis approach, we identified lysine 260 of MAP3K2 as the single site of methylation catalysed by SMYD3 ( Fig. 3e ; data not shown). The immediate sequence surrounding K260 of MAP3K2 and K5 of H4 is identical (GKGG), although the catalytic efficiency (k cat /K M ) of SMYD3 for MAP3K2 is nearly two orders of magnitude greater than it is for H4 (Extended Data Fig. 6c ). We also did not detect any methylation of H3 at lysine 4 by SMYD3, a previously reported activity 4 (Extended Data Fig. 6d, e ). In addition, SMYD3 was the only KMT of the eleven we tested that could methylate MAP3K2 ( Fig. 3f , g; Extended Data Fig. 6f ). Furthermore, whereas SMYD3 methylated MAP3K2, it had no detectable activity on a dozen other members of the MAP kinase signalling cascade ( Fig. 3h ). Finally, in vitro methylation assays on MAP3K2 peptides spanning K260 (amino acids 249 to 273) with K260 either unmethylated, mono-, di-or tri-methylated showed that SMYD3 can use all lower states of methylation as substrates to generate the fully saturated trimethyl state at K260 (Extended Data Fig. 6g , h). Thus, SMYD3 mono-, di-and tri-methylates MAP3K2 at lysine 260 (MAP3K2-K260me) with high specificity in vitro.
To investigate MAP3K2 methylation in cells, we raised methyl-specific antibodies against the different states of methylation at K260 (Extended Kras;Smyd3 (n 5 8) mutant mice. The grade of lesions is indicated. i, Kaplan-Meier survival of Kras;p53 mutant mice (p48 Cre/1 ; Kras LSL-G12D/1 ;p53 lox/lox , n 5 33, median survival 5 56 days) and Kras;p53;Smyd3 mutant mice (n 5 21, median survival 5 68.5 days) animals. P 5 0.0005 by log-rank test for significance. j, Immunoblots with the indicated antibodies of Kras;p53 and Kras;p53;Smyd3 mutant pancreatic tumour lysates. Loss of SMYD3 was also confirmed by immunostaining of pancreatic sections (Extended Data Fig. 4d 
Kras; Smyd3
Kras f, Immunoblots of lung tumour lysates dissected from Kras and Kras;Smyd3 mutant mice (two independent biological replicates for each genotype) with the indicated antibodies. Loss of SMYD3 was also confirmed by immunostaining on lung sections (Extended Data Fig. 3f ).
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Data Fig. 6i ). In co-transfection experiments in human 293T cells, overexpressed MAP3K2 was methylated at K260 upon SMYD3 overexpression (Extended Data Fig. 6j ). Endogenous methylation at MAP3K2-K260 was observed in LKR10 cells and RNAi-mediated depletion of SMYD3 in these cells resulted in loss of this signal (Fig. 3i ). Finally, the MAP3K2-K260me2/3 signal was significantly reduced in tumour tissue microdissected from Kras versus Kras;Smyd3 mutant mice ( Fig. 3j ). Thus, SMYD3 is required for maintenance of physiological levels of MAP3K2-K260 methylation in cancer tissue and cells. The cytoplasmic kinase MAP3K2 is activated in response to a variety of stress and mitogenic stimuli, including epidermal growth factor (EGF), and relays signals to downstream MAP kinase components such as ERK1/2 18 and ERK5 19 . Given that the pERK1/2 and pERK5 signals are reduced in LAC and PDAC samples from Smyd3 mutant mice (Figs 1 and 2; Extended Data Fig. 3 ), we reasoned that SMYD3-mediated methylation of MAP3K2 may regulate signalling within the Ras/ERK pathway. We therefore examined the relationship between SMYD3 and EGF-stimulated ERK1/2 activation. First, endogenous SMYD3 was depleted in LKR10 cells by shRNA targeting the 39 untranslated region of Smyd3 and then we reconstituted the depleted cells with RNAi-resistant wild-type SMYD3 or catalytically inactive SMYD3(F183A). In control cells, EGF treatment triggered ERK1/2 phosphorylation, and this response was greatly reduced by SMYD3 depletion (Fig. 4a ). Complementation with wild-type SMYD3 re-established the EGF-mediated ERK1/2 phosphorylation response, whereas complementation with SMYD3(F183A) failed to do so ( Fig. 4a ). SMYD3 was also required when serum was used to activate ERK1/2 activation in LKR10 cells (Extended Data Fig. 7b ) and when EGF was used to activate ERK1/2 in human lung and pancreatic cancer cells (Extended Data Fig. 7c, d ). Finally, we established a MAP3K2 complementation system to investigate the role of K260 of MAP3K2. In these experiments, wild-type MAP3K2, but not the SMYD3resistant MAP3K2(K260A) mutant, reconstituted the EGF-mediated ERK1/2 phosphorylation response ( Fig. 4b ).
To characterize how the SMYD3-MAP3K2 axis impinges on the overall MAP kinase network, the level of EGF-induced activation for several kinases was determined in control, SMYD3 knockdown and MAP3K2 knockdown LKR10, A549 and CFPac1 cells ( Fig. 4c ; Extended Data Fig. 7a-d ). SMYD3 and MAP3K2 were both required for full activation of ERK5, ERK1/2, MEK1/2 and JNK (known downstream targets of MAP3K2; refs 18-22), but dispensable for activation of AKT and CRaf (RAF-1) (p38 was not activated in the cell lines tested; Extended Data Fig. 7a-d) . Notably, MEK1/2 activation was impaired in SMYD3 and MAP3K2 knockdown cell lines. As the canonical ERK1/2 activation pathway consists of Raf-MEK1/2-ERK1/2 and both SMYD3 and MAP3K2 were required for MEK1/2 and ERK1/2 activation but not CRaf, we postulated that SMYD3 methylation of MAP3K2 directly influences MEK1/2 phosphorylation. Indeed, pMEK1/2 signal increased in response to overexpression of wild-type MAP3K2 and a SMYD3resistant MAP3K2(K260A) mutant, but not a catalytically dead MAP3K2 (K385M) mutant 23 (Fig. 4d , e; Extended Data Fig. 7e ). SMYD3 expression alone had no effect on MEK1/2 activation (Extended Data Fig. 7e ), but resulted in increased MEK1/2 phosphorylation when co-expressed with wild-type MAP3K2 relative to co-expression with MAP3K2(K260A) ( Fig. 4d, e ). Notably, MAP3K2 phosphorylates MEK1 in in vitro kinase assays 21 , and this activity was unchanged if SMYD3-methylated MAP3K2 or MAP3K2(K260A) were used in the kinase assays rather than wild-type, unmethylated MAP3K2 (Extended Data Fig. 7f ). These results indicate that the molecular mode of action linking MAP3K2 methylation to MEK1/2 activation is not due to changes in the intrinsic kinase activity of MAP3K2 but rather another mechanism.
Given the role of SMYD3-MAP3K2 in activating MEK1/2, we tested whether SMYD3 depletion augments the effects of the MEK1/2 inhibitor trametinib, which is currently being investigated to treat NSCLC and PDAC (http://clinicaltrials.gov/). Administration of Kras and Kras;Smyd3 mutant mice with a normal dose of trametinib blocked tumorigenesis in both strains, although phosphorylation of ERK1/2 was still lower in mice depleted of SMYD3 (Extended Data Fig. 8 ). Notably, a low-dose trametinib regimen, which only partially inhibited pERK1/2 levels and the formation of neoplastic lesions in Kras mutant mice, was sufficient to block tumorigenesis and ERK1/2 activation in Smyd3 knockouts (Extended Data Fig. 8 ). Trametinib was also more potent in cancer cell lines when coupled with SMYD3 depletion (Extended Data Fig. 9a ). These data indicate that SMYD3 may act in concert with MEK1/2 signalling In vitro methylation assay as in d with the indicated proteins on MAP3K2 amino acids 1-350, MAP3K2 amino acids 1-350 with a K260A substitution, and MAP3K2 amino acids 351-619. Arrow indicates GST, which is a stable breakdown product of recombinant proteins. f, g, MAP3K2 is a specific substrate of SMYD3. In vitro methylation assays as in d on MAP3K2 using the indicated KMTs (positive controls for the known KMTs shown in Extended Data Fig. 6f ). h, SMYD3 specifically methylates MAP3K2. In vitro SMYD3 methylation assay as in d on the indicated MAP kinase pathway proteins. Asterisk indicates MAP3K2 breakdown product. Arrow indicates GST, which is a stable breakdown product for many of the screened substrates. i, Immunoblots with the indicated antibodies from input (cytoplasmic extract) or the indicated IPs (immunoprecipitations) from LKR10 cells stably expressing control or Smyd3 shRNA. j, Immunoblots with the indicated antibodies and samples as in i of lung tumour biopsy lysates isolated from Kras and Kras;Smyd3 mutant mice. Asterisks represent detection of IgG. For experiments e-k representative data based on three or more independent biological replica are shown.
LETTER RESEARCH in tumorigenesis. Indeed, overexpression of activated MEK1(S218D, S222D) (MEK1-DD) 24 rescued the effects of SMYD3 depletion in lung cancer cells (Extended Data Fig. 9b )
Because the intrinsic kinase activity of MAP3K2 is not directly altered by methylation, we postulated that this modification event was involved in modulating a key protein-protein interaction. To identify candidate methyl-sensitive binding partners of MAP3K2, a SILAC (stable isotope labelling by amino acids in cell culture)-based quantitative proteomic screen was performed with cytoplasmic extracts to isolate proteins that bound differentially to MAP3K2-K260me0 peptides versus MAP3K2-K260me3 peptides. Although this analysis did not show enrichment of any K260me3-binding proteins, it did reveal six candidates that bind to the unmethylated peptide but are blocked by K260 trimethylation. Of these six proteins, three are members of the PP2A serine/threonine phosphatase complex (Fig. 4f ). In our proteomics experiment we identified the catalytic PPP2CA protein, the structural PPP2R1A protein and the regulatory PPP2R2A protein, three classes of subunits that comprise the typical heterotrimeric PP2A complex. This complex is a major cellular phosphatase that inactivates key members of the MAP kinase signalling cascade (reviewed in refs 25, 26) . We found that the interaction between the PP2A complex and MAP3K2 is direct, as recombinant PPP2R2A, but not PPP2R1A, bound to MAP3K2-K260me0 peptides and not to MAP3K2-K260me3 peptides in in vitro peptide pull-down experiments ( Fig. 4g; top panel) . Moreover, PPP2R2A was specifically recovered from cytoplasmic extracts using MAP3K2-K260me0 peptides but not by MAP3K2-K260me3 peptides ( Fig. 4g; middle panel) . Thus, amino acids 249-273 of MAP3K2 are sufficient for binding directly to the PP2A complex, via PPP2R2A, and methylation at K260 inhibits this interaction.
We next tested the ability of the PP2A inhibitor cantharidin 27 to 'phenocopy' SMYD3 function ( Fig. 4h; Extended Data Fig. 10a-d) . Cantharidin treatment had no gross effect on tumour formation in p48 1/Cre Kras mutant mice relative to vehicle treatment; in contrast, administration of cantharidin to p48 1/Cre Kras;Smyd3 mutant mice restored tumour formation to the level seen with wild-type SMYD3 in the p48 1/Cre Kras mutant mice. These data suggest an in vivo functional connection between the Ras pathway, SMYD3 and PP2A.
We have identified SMYD3-catalysed methylation of MAP3K2 as a key event regulating Ras signalling in cancer cells. Although MAP3K2 was shown to phosphorylate MEK1/2 directly, a complete understanding of how MAP3K2 functions in Ras signalling remains to be determined. Our data suggest a model in which increased SMYD3 activity generates a population of methylated MAP3K2, which-via mechanisms such as blocking the association of the PP2A phosphatase with components of the MAP kinase network-intensifies the output of this pathway in response to oncogenic Ras (Extended Data Fig. 10e ). In addition, the cytoplasmic localization of the SMYD3-MAP3K2 dynamic suggests a paradigm for how signalling through lysine methylation and phosphorylation can be integrated to regulate key signal transduction cascades. A clinical implication of this work is the identification of SMYD3 as a candidate therapeutic target for pharmacologic intervention to treat pancreatic and lung cancers, as well as potentially other Rasdriven tumours. The complete loss of SMYD3 function has no visible phenotype in mice, suggesting that SMYD3 inhibitors would have minimal collateral toxicity as chemotherapeutics. Thus, one could envision a therapeutic strategy comprising inhibitors of Raf or MEK that are currently used in the clinic with a SMYD3 inhibitory agent, which could mitigate potential drug toxicity by lowering the overall dose needed for each medicine and combat the development of resistance. Together, our findings reveal a new function for lysine methylation signalling in the cytoplasm in the regulation of cancer pathways.
METHODS SUMMARY
Animal studies were performed according to practices prescribed by the NIH at Stanford's Research Animal Facility accredited by the Association for Assessment and Accreditation of Laboratory Animal Care. The Smyd3 mutant mice used in lung and pancreatic cancer experiments were initially obtained from the KOMP Repository. SILAC was performed using HeLa cells extracts grown in either normal amino acids culture condition ('light') or using modified amino acids culture condition ('heavy'). Full methods and data analysis are described in detail in Methods. pathways and repels PP2A. a, SMYD3 catalytic activity is required for ERK1/2 activation in LAC cells. Immunoblots with the indicated antibodies of LKR10 cells lysates depleted for SMYD3 and reconstituted with either active or inactive Flag-SMYD3 as indicated. Stimulation, EGF treatment for 15 min at 25 ng ml 21 . b, MAP3K2 methylation is required for ERK1/2 activation in LAC cells. Immunoblot with the indicated antibodies of LKR10 cells lysates treated as in a depleted for MAP3K2 and reconstituted with either wild-type or K260A mutant Flag-MAP3K2. c, SMYD3 and MAP3K2 regulate multiple overlapping MAP kinase pathway proteins. Quantification of the indicated activated kinase signals in shSMYD3 and shMAP3K2 relative to shControl cell lysates based on three independent biological replica treated as in Extended Data Fig. 7a . d, SMYD3 catalytic activity promotes MAP3K2-induced phosphorylation of MEK1/2. Immunoblots with the indicated antibodies of 293T cells lysates transfected with Flag-MAP3K2 and haemagglutinin (HA)-SMYD3 wild-type and derivatives as indicated. MAP3K2(K385) is a kinase-dead mutant. e, Quantification of pMEK and pERK1/2 signals in 293T cells transfected with the indicated MAP3K2 and SMYD3 constructs and treated as in d. Data were generated from three independent biological replica. 
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METHODS
Ethics statement. Mice were maintained according to practices prescribed by the NIH at Stanford's Research Animal Facility accredited by the Association for Assessment and Accreditation of Laboratory Animal Care. Mouse strains. Kras 1/LSL-G12D , p53 lox/lox , and p48 1/Cre mice have been described before 8, 28, 29 . Smyd3 tm1a(KOMP)Wtsi mice were obtained from the KOMP Repository. Details on the targeted allele are available on the KOMP website 6 . Briefly, mice were constructed using the 'knockout first' strategy. In this allele, insertion of a LacZ cassette with strong splice acceptor in intron 2 of the Smyd3 gene creates a knockout allele serving additionally as a reporter. Expression of the Cre recombinase in cells removes the LacZ cassette and further deletes several Smyd3 exons, resulting in a null allele (Extended data Fig. 2d ). Mice were of mixed C57BL/6;129SV background and we systematically used randomly picked littermates as controls in all the experiments (sex ratio per cohort balanced Lung cancer mouse models Adenovirus-induced lung adenocarcinoma (LAC). Kras LSL-G12D (Kras) and Kras LSL-G12D ;Smyd3 lox/lox (Kras;Smyd3) mice were treated with 5 3 10 6 plaqueforming units of adenovirus expressing Cre (University of Iowa adenovirus core) by intratracheal infection as previously described 31 . Tumours were analysed and quantified at 12, 16 and 20 weeks post-infection, n 5 6 for each group. Lentivirus-induced lung adenocarcinoma. Generation of a dual promoter lentiviral vector for Cre and cDNA expression was described before 32 . To determine the effect of reconstitution of exogenous Smyd3 WT and Smyd3 F183A expression on lung tumour progression a lentiviral vector was developed that expressed both the Smyd3 complementary DNA and Cre. A lentivirus expressing Cre alone was used as a control. Virus was produced and titred as described previously 33 . Briefly, the lenti-Cre vector was co-transfected with packaging vectors into 293T cells using calcium-phosphate. The supernatant was collected at 48 and 72 h. Concentrated virus was recovered by ultracentrifugation at 25,000 r.p.m. for 90 min and resuspended in PBS. Cohorts of Kras LSL-G12D ;Smyd3 lox/lox (Kras;Smyd3) mice were infected with each lentiviral vector. Tumour burden was analysed 24 weeks after lentiviral infection, n 5 4 for each treatment.
Preparation of pancreatic epithelial explants culture. Pancreatic epithelial explants from 4-to 6-week-old p48 Cre/1 (WT) and p48 Cre/1 ;Smyd3 lox/lox (Smyd3) were established by modification of previously published protocols 34 . In brief, the whole pancreas was collected and treated twice with 1.2 mg ml 21 collagenase VIII (Sigma-Aldrich). Following multiple wash steps with McCoy's medium containing soybean trypsin inhibitor (SBTI, 0.2 mg ml 21 ), digested samples were filtered through a 100-mm filter, resuspended in culture medium (Waymouth's MB 752/1 supplemented with 0.1% BSA, 0.2 mg ml 21 SBTI; 50 mg ml 21 bovine pituitary extract, 10 mg ml 21 insulin, 5 mg ml 21 transferrin, 6.7 ng ml 21 selenium in 30% FCS) and allowed to recover for 1 h at 37 uC. Thereafter, cells were pelleted and resuspended in culture medium supplemented with penicillin G (1,000 U ml 21 ), streptomycin (100 mg ml 21 ), amphotericin B (0.25 mg ml 21 ), 0.1% FCS, and an equal volume of rat tail collagen type I (BD Bioscience). The cellular/rat tail collagen type I suspension was immediately plated on plates pre-coated with 2.5 mg ml 21 of rat tail collagen type I. In stimulation experiments recombinant human EGF (rhEGF, Invitrogen) was added at final concentration of 25 ng ml 21 . For quantification, acinar explants were seeded in triplicates. Cells clusters were counted from at least 3 optical fields/well and reported as a percentage of acinar clusters and duct-like spheres. The quantification was performed in two independent experiments; the number of mice is reported in the main text. Lentiviral transduction of pancreatic epithelial explants. For reconstitution experiments fresh explants from Kras LSL-G12D ;Smyd3 lacZ/lacZ (Smyd3 deficient) were transduced using lentiviral vectors with or without Cre and expressing wild-type SMYD3 or SMYD3(F183A). Cre-mediated recombination results in oncogenic K-Ras activation, causing spontaneous ADM (acinar to ductal metaplasia), which was quantified as described above.
Immunofluorescence of pancreatic epithelial explants. For immunofluorescent labelling of explanted pancreatic acini/duct clusters, collagen gels containing explanted pancreas were fixed in the chamber slides in 4:1 methanol:DMSO overnight at 4 uC, washed and stored at -20 uC in 100% methanol. Collagen gels were permeabilized with TritonX-100 0.1% (Sigma-Aldrich) for 5 min at room temperature and washed in PBS1TritonX-100 0.025% (PBST). Gels were blocked with 5% normal goat serum in PBST1BSA 2% for 2 h at room temperature, then incubated sequentially with SMYD3 primary antibody (Abcam) and Alexa Fluor 488conjugated secondary antibody diluted in blocking buffer overnight at 4 uC. Following each antibody, gels were washed in PBST. Cells were counterstained with 50 mg ml 21 DAPI (Invitrogen) and washed in PBS. Images were captured on a Zeiss inverse fluorescent microscope. Identical acquisition methods were used for all samples to allow direct comparison of the resulting images.
Histology, immunohistochemistry and X-gal staining. Tissue specimens were fixed in 4% buffered formalin for 24 h and stored in 70% ethanol until paraffin embedding. 3-mm sections were stained with haematoxylin and eosin (HE) or used for immunohistochemical studies.
Immunohistochemistry. Immunohistochemistry was performed on formalinfixed, paraffin embedded mouse and human tissue sections using a biotin-avidin method as described before 35 . The following antibodies were used: rabbit anti-Amylase (Sigma-Aldrich), pERK1/2 (Cell Signaling), MUC5 (NeoMarkers) and SMYD3 (Abcam). Sections were developed with DAB and counterstained with haematoxylin. Pictures were taken using a Zeiss microscope equipped with the AxioVision software. Analysis of the tumour area and IHC analysis was done using ImageJ software by measuring pixel units. X-gal staining. Staining of cryosections (8 mm) was carried out as described previously 35 ; slides were counterstained with nuclear fast red. qRT-PCR. RNA was isolated using the Qiagen RNeasy Isolation Kit followed by cDNA synthesis (SuperScript II, Invitrogen). Real-time PCR was performed with 800 nM primers diluted in a final volume of 20 ml in SYBR Green Reaction Mix (Applied Biosystems). RT-PCRs were performed as follows: 95 uC for 10 min, 35 cycles of 95 uC for 15 s and 60 uC for 1 min. qRT-PCR data are representative of 4 independent mouse pancreatic epithelial explants isolations per treatment. All samples were analysed in triplicate. Gapdh expression was used for normalization.
The following primers were used: Smyd3-For 59-TGCGCACCATGGAGCCGTAC Smyd3-Rev 59-GTCAAAGGCCAGCCTCAGGTTCT Gapdh-For 59-CCCACTAACATCAAATGGGG Gapdh-Rev 59-CCTTCCACAATGCCAAAGTT Meta-analysis of public PDAC and NSCLC data sets. We downloaded raw data for gene expression studies (7 pancreatic cancer, 6 NSCLC) from the NCBI GEO and EBI ArrayExpress. After re-annotating the probes, each data set was normalized separately using gcRMA. We applied two meta-analyses approaches to the normalized data. The meta-analysis approach has been recently described 36 . Briefly, the first approach combines effect sizes from each data set into a meta-effect size to estimate the amount of change in expression across all data sets. For each gene in each data set, an effect size was computed using Hedges' adjusted g. If multiple probes mapped to a gene, the effect size for each gene was summarized using the fixed effect inverse-variance model. We combined study-specific effect sizes to obtain the pooled effect size and its standard error using the random effects inverse-variance technique. We computed z-statistics as a ratio of the pooled effect size to its standard error for each gene, and compared the result to a standard normal distribution to obtain a nominal P value. P values were corrected for multiple hypotheses testing using false discovery rate (FDR) 37 . We used a second non-parametric meta-analysis that combines P values from individual experiments to identify genes with a large effect size in all data sets. Briefly, we calculated a t-statistic for each gene in each study. After computing one-tail P values for each gene, they were corrected for multiple hypotheses using FDR. Next, we used Fisher's sum of logs method, which sums the logarithm of corrected P values across all data sets for each gene, and compares the sum against a chi-square distribution with 2k degrees of freedom, where k is the number of data sets used in the analysis.
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Plasmids. Bacterial expression plasmids were created using pGEX-6P1 vector. Transient mammalian expression plasmids were created using pCDNA3.1 HA, pCDNA3.1 Myc and pCagFlag vectors. The different inserts were amplified by PCR using either cDNA or specific clones from the human ORFeome library as template. Singlepoint mutations of SMYD3 and MAP3K2 were generated using the QuikChange site-directed mutagenesis protocol (Stratagene), and clones were confirmed by DNA sequencing. SMYD3 and MAP3K2 shRNA targeting UTR regions were cloned in a pSICOR vector carrying a puromycin resistance gene. Human SMYD3 shRNA sequence directed against the 39 UTR TGCGTGTG TCTTTGTTGAATTTCAAGAGAATTCAACAAAGACACACGCTTTTTTC.
Human MAP3K2 shRNA sequence directed against the 39 UTR TGGATGA TTTCACTAGGCATTTCAAGAGAATGCCTAGTGAAATCATCCTTTTTTC.
Mouse Smyd3 shRNA sequence directed against the 39 UTR TGAGCAGAACC ATTACAATATTCAAGAGATATTGTAATGGTTCTGCTCTTTTTTC.
Mouse Map3k2 shRNA sequence directed against the 39 UTR TAGTCATAGC TATAGTGAAATTCAAGAGATTTCACTATAGCTATGACTTTTTTTC. SMYD3 and MAP3K2 stable reconstitution plasmids have been created using the Gateway cloning system according to the manufacturer's instructions (Invitrogen) with either the WT or point mutant constructs, into pMSCV-Flag and pBabe-Flag vectors (hygromycin resistance). Cell culture, reagents and transfections. K-Ras mutant lung and pancreatic carcinoma lines LKR10 (mouse lung), A549 (human lung) and CFPac1 (human pancreas) were used (all these cell lines are wild-type for EGFR, see below and the COSMIC database for the human cell lines). 293T, LKR10, A549 and CFPac1 cells were grown in Dulbecco's modified Eagle's medium (GIBCO) supplemented with 10% fetal calf serum (FCS, GIBCO), 100 units ml 21 penicillin/streptomycin and glutamine. All cells were cultured at 37 uC in a humidified incubator with 5% CO 2 . For transient expression, cells were transfected using Mirus 293T transfection reagent and collected 24 to 36 h later. For stable knockdown, cells were transduced with lentiviral shRNA constructs using the packaging vectors pGagpol and pD8.2, followed by 2 mg ml 21 puromycin selection for one week. For rescue experiments, cells were transduced with retroviral pBabe and pMSCV constructs using packaging the pGag and pVSVg vectors, followed by 100 mg ml 21 hygromycin selection for one week.
Serum and EGF stimulation were performed after 48 h of serum-starvation using either regular 10% FBS cell media or 25 ng ml 21 of rhEGF (Promega) for 15 min. EGFR sequencing. LKR10 DNA was isolated. Egfr exons 18 to 21 were amplified using a proofreading polymerase (PfuUltra, Invitrogen) and sequenced bi-directionally. Sequence was verified based on transcript ID: ENSMUST00000020329. The following primers were used: mEGFR-Exon 18: For-59CTCTGGCTCAGAATGAATCTAC, Rev-59GAAGCCT AGTGCGGACCTGTC, product: 268 bp. mEGFR Exon 19: For-59CCAGCTCACAAGGCAACATG, Rev-59CTAAGGAAG CAAGATTGACC, product: 229 bp. mEGFR Exon 20: For-59GATTCATCTATTGTCCTTACC, Rev-59TGGGTACT TCAGTGGACAGAC, product: 234 bp. mEGFR Exon 21: For-59CATGACACTGAGGATGCCCAGA, Rev-59CAAATGC TGCCCACAGCTGAC, product: 298 bp. Cell extracts, immunoprecipitation and immunoblot analysis. For total cell extracts, cells were lysed in RIPA buffer (10 mM Tris-HCl pH 8, 140 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 1% Triton, 0.1% SDS, 1 mM PMSF, protease inhibitors (Roche) and a phosphatase inhibitor cocktail (Sigma-Aldrich)) for 15 min. Cell fractionation was performed by collecting supernatant (cytoplasmic fraction) after 5 min of 1,300g centrifugation following a 10 min incubation in hypotonic buffer (10 mM HEPES pH 7.9, 10 mM KCl, 1.5 mM MgCl 2 , 0.34 M sucrose, 10% glycerol, 1 mM DTT, 0.05% Triton, and protease inhibitors). The pellet was then incubated 15 min in LSDB250 buffer (glycerol 20%, MgCl 2 3 mM, HEPES pH 7.9 50 mM, KCl 250 mM, DTT 0.5mM, PMSF 0.5 mM, NP40 0,1%, protease inhibitors), and centrifuge at 15,000g for 10 min. The supernatant was collected as soluble nuclear extract, and the pellet was further extracted in LSDB250 buffer with sonication (chromatin fraction). Protein concentration was determined by the BCA assay (Pierce).
For immunoprecipitation, cells were lysed in either LSDB250 buffer for smooth total cell extract, or hypotonic buffer for cytoplasmic extract, and same amount of protein extracts were incubated with specific antibody overnight at 4 uC. Extracts were then incubated with protein A Sepharose beads (GE Healthcare) for 2 h at 4 uC.
Proteins were resolved by SDS-PAGE, transferred to nitrocellulose membrane and analysed by immunoblot. Antibodies used were as follows: SMYD3 and MAP3K2me2/3 (generated by Yenzym); GST (generated by Covance); beta-tubulin (05-661 Millipore); MAP3K2 (1662-1 Epitomics); Flag and ERK5 (F1804, E1523, Sigma); pERK1/2 and ERK1/2 and pMEK1/2 and MEK1/2 and pJNK and JNK and pP38 and P38 and pERK5 and pAKT and AKT and pCRaf and CRaf, PPP2R2a (4370, 4695, 9121, 9122, 9251, 9252, 9211, 9212, 3371, 2965, 4685, 9427, 9422, 5689, Cell Signaling); HA and Myc (26183, 21316 Pierce). Immunoblots signal intensity was measured using ImageJ software. Quantification data are expressed as s.e.m. Expression and purification of recombinant proteins. For expression of GST tagged recombinant proteins, transformed BL21 cells were induced with 0.1 mM IPTG overnight at 20 uC, and proteins were purified using glutathione Sepharose beads (GE Healthcare) and eluted in 10 mM reduced glutathione (Sigma) or cleaved from the GST tag using purified Precision enzyme. Recombinant human histone H3 and H3K4* mutant (first thirteen lysines mutated to arginine except lysine K4) were expressed and purified as previously described 38 . ProtoArray, methylation and kinase assays. In vitro methylation assays were performed using 1 to 2 mg of recombinant proteins or peptides incubated with 1 mg of recombinant methyltransferases and 0.1 mM of S-adenosyl-methionine (SAM, Sigma) or 2 mCi 3 H-AdoMet (American Radiolabelled Chemicals) in buffer containing 50 mM Tris-HCl (pH 8.0), 10% glycerol, 20 mM KCl, 5 mM MgCl 2 , and 1 mM PMSF at 30 uC overnight. The reaction mixture was resolved by SDS-PAGE, followed by autoradiography, Coomassie stain (Pierce) or mass spectrometry analysis.
Kinetic constants k cat and K M were determined using Grafit (Erithacus software) from SMYD3 methylation activity on histone H4 (EMD Millipore, USA) and MAP3K2 (Origene, USA) was assessed by radiometric assays using [ 3 H]SAM with specific product capture on arginine binding SPA beads for assays using histone substrates or RNA binding SPA beads when MAP3K2 was the substrate. (PerkinElmer, USA). Assay conditions were 20 mM Tris pH 8, 3 mM DTT, 50 mM ZnCl 2 , 0.005% Tween-20, 1.2 mM unlabelled SAM, 0.2 mM [ 3 H]SAM and 25 nM SMYD3 final. Reactions were quenched using 2 mM unlabelled SAM. SPA signal was quantified in a Microbeta scintillation counter (PerkinElmer, USA). Data were fit to the Michaelis-Menten equation 6 , where the rate was plotted as a function of the concentration of substrate.
To verify the activity of the other lysine methyltransferases tested, in vitro methylation assays were performed using known substrates, as previously reported [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] .
In vitro kinase assays were performed by incubating 1 mg of recombinant MAP3K2 WT or mutants with 1 mg of recombinant MEK1 in kinase buffer containing 25 mM Tris-HCl (pH 7.5), 5 mM b-glycerophosphate, 2 mM dithiothreitol (DTT), 0.1 mM Na3VO4, 10 mM MgCl 2 and 200 mM ATP (Cell Signaling) at 37 uC during 30 min. Peptide pull-down and SILAC. MAP3K2 peptides were generated by 21st Century Biomedicals and are based on the following sequence: DYDNPIFEKFGKGGTYP RRYHVSYHG[K-Biot-Ahx]-amide.
For peptide pull-downs, 5 to 10 ml of streptavidin Sepharose beads (GE Healthcare) were saturated with 10 mg of specific biotinylated peptides for 2 h at 4 uC under rotation in peptide buffer (50 mM Tris pH 7.5, 150 mM NaCl, 1% NP-40), then washed 3 times in the same buffer. Beads were then incubated with either 1 mg of recombinant proteins or 1 mg of HeLa cytoplasmic extract for 4 h at 4 uC under rotation in peptide buffer. Beads were then washed 3 times in the same buffer and resuspended in Laemmli buffer for immunoblot analysis.
For SILAC peptide pull-down, HeLa cytoplasmic extracts were prepared from cells cultivated in either normal amino acids culture condition ('light') or using modified amino acids culture condition ('heavy'). A 2-way experiments was performed, the 'forward' condition combining MAP3K2-K260me0 peptide with light extract and MAP3K2-K260me3 peptide with heavy extract, the 'reverse' condition combining MAP3K2-K260me3 peptide with light extract and MAP3K2-K260me0 peptide with heavy extract. Beads of each pair of peptide pull-down were then pooled together, washed and extracts were resuspended in Laemmli buffer and resolved by SDS-PAGE. In-gel trypsin digestion was performed and peptides purified using C18 stage tips (Fisher) before mass spectrometry analysis to quantify the ratio of each potential binders for K260me0 and K260me3 peptides, in forward and reverse condition. To identify outliers in both the forward and the reverse experiment, boxplot statistics was applied (cut off 5 1.53 interquartile range). Proteins identified as outlier in both experiments are assigned as significant interactors. Amino acid complements used for SILAC are L-lysine-2HCl (Thermo Scientific 88429), L-arginine-HCl (Thermo Scientific 88427), 2 H 4 -L-lysine-2HCl (Thermo Scientific 88438), 13 C 6 -L-arginine-HCl (Thermo Scientific 88433), L-proline (Thermo Scientific 88430). Active Ras pull-down and detection. Ras activity refers to the level of guanosine triphosphate-bound Ras, which is able to bind Ras binding domain (RBD) of RAF-1 as measured using a RBD-domain pull-down assay kit as recommended by the manufacturer (The Active Ras Pull-Down and Detection Kit, Thermo Scientific). Briefly, tumour biopsies were homogenized on ice in lysis buffer containing 25 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (pH 7.5), 1% Igepal CA-630, 150 mM NaCl, 0.25% sodium deoxycholate, 10% glycerol, 25 mM NaF, 10 mM MgCl 2 , 1 mM EDTA, 10 mg ml 21 aprotinin, 10 mg ml 21 leupeptin and 1 mM sodium orthovanadate. These samples were sonicated and centrifuged at 15,000g for 10 min at 4 uC to remove cellular debris. Protein concentration was measured. Equal amounts LETTER RESEARCH of lysate were incubated for 30 min at 4 uC with agarose beads coated with RBD. The beads were then washed three times with ice-cold lysis buffer, boiled for 5 min at 95 uC, and active Ras was analysed by immunoblotting following standard protocol using Ras-specific antibodies (Thermo Scientific). For comparison to total Ras protein, 2% of total lysates used for pull-down was analysed by immunoblot. Cancer xenografts. For xenograft analysis, 500,000 CFPac1 cells were injected into the flank of NSG mice with Matrigel (BD Bioscience). Tumour volume was measured at the times indicated and calculated using the ellipsoid formula (length 3 width 2 ). Cell assays. Anchorage-independent growth was assessed in soft agar assays. Cell proliferation was assessed by counting cell number at indicated days and expressed relative to the control as previously described 6 . Cell viability in response to treatment with the MEK inhibitor trametinib (Selleckchem) was measured by an MTT assay (Roche) according to the manufacturer's instructions. Statistics. Kaplan-Meier survival curves were calculated using the survival time for each mouse from all littermate groups. The log-rank test was used to test for significant differences between the groups. For image quantification and gene expression analysis statistical significance was assayed by Student's t-test with the Prism GraphPad software (two-tailed unpaired and paired t-test depending on the experiment; variance was first systematically examined using an F-test). *P value , 0.05; **P value , 0.01; ***P value , 0.001; ns, not significant. Data are represented as mean 6 standard error of the mean (s.e.m.).
